It is well known that the cetuximab (Cet) epidermal growth factor receptor (EGFR) antibody enhances the sensitivity of tumour cells to radiation, and it is likely that the concurrent administration of Cet and radiotherapy (RT) results in some degree of interplay between the effects of the individual agents on the skin and in the exacerbation of reactions normally seen with these individual agents. In this paper, we present a concise review of Cet/RT-related skin toxicity, focusing on mechanisms and pathogenesis, clinical presentation and scoring systems and, finally, therapeutic management. © 2013 S. Karger AG, Basel.
Management of 'In-Field' skin toxicity in head and neck cancer patients treated with combined cetuximab and radiotherapy
Cante D.;Franco P.Membro del Collaboration Group
;Sciacero P.;Marra A.;
2013-01-01
Abstract
It is well known that the cetuximab (Cet) epidermal growth factor receptor (EGFR) antibody enhances the sensitivity of tumour cells to radiation, and it is likely that the concurrent administration of Cet and radiotherapy (RT) results in some degree of interplay between the effects of the individual agents on the skin and in the exacerbation of reactions normally seen with these individual agents. In this paper, we present a concise review of Cet/RT-related skin toxicity, focusing on mechanisms and pathogenesis, clinical presentation and scoring systems and, finally, therapeutic management. © 2013 S. Karger AG, Basel.| File | Dimensione | Formato | |
|---|---|---|---|
|
definitive.pdf
file disponibile solo agli amministratori
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
453.76 kB
Formato
Adobe PDF
|
453.76 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
